Circulation, Vol 66, 334-338, Copyright © 1982 by American Heart Association
LJ Rubin, BM Groves, JT Reeves, M Frosolono, F Handel and AE Cato
To evaluate the effects of prostacyclin (prostaglandin I2) on pulmonary
vascular tone in primary pulmonary hypertension (PPH), we performed
right-heart catheterization on seven patients with PPH and made hemodynamic
measurements before and after infusing incremental doses of prostacyclin.
In maximal doses of 2-12 mg/kg/min (mean 5.7 +/0 3.1 ng/kg/min),
prostacyclin reduced mean pulmonary arterial pressure from 62 +/- 15 to 55
+/- 16 mm Hg (p less than 0.05) and total pulmonary resistance from 17.1
+/- 8.7 to 9.7 +/- 5.9 units (p less than 0.005), and increased cardiac
output from 4.22 +/- 1.64 to 6.57 +/- 2.04 l/min (p less than 0.01). Heart
rate increased from 83 +/- 13 to 94 +/- 11 beats/min (p = 0.1) and mean
systemic arterial pressure decreased from 90 +/- 12 to 77 +/- 4 mm Hg (p =
0.055). Three patients who received a continuous infusion of prostacyclin
for 24-48 hours had sustained reductions in total pulmonary resistance
during the infusion period. These data demonstrate that prostacyclin can
increase cardiac output and reduce pulmonary arterial pressure and
resistance in PPH.
ARTICLES
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension
This article has been cited by other articles:
 |
|
 |
|
  D. Montani, X. Jais, L. C. Price, L. Achouh, B. Degano, O. Mercier, S. Mussot, E. Fadel, P. Dartevelle, O. Sitbon, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease Eur. Respir. J., December 1, 2009; 34(6): 1348 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z-C Jing, X Jiang, B-X Wu, X-Q Xu, Y Wu, C-R Ma, Y Wang, Y-J Yang, J-L Pu, and W Gao Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study Heart, September 15, 2009; 95(18): 1531 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. P. Laumanns, L. Fink, J. Wilhelm, J.-C. Wolff, R. Mitnacht-Kraus, S. Graef-Hoechst, M. M. Stein, R. M. Bohle, W. Klepetko, M. A. R. Hoda, et al. The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 683 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Baliga, L. Zhao, M. Madhani, B. Lopez-Torondel, C. Visintin, D. Selwood, M. R. Wilkins, R. J. MacAllister, and A. J. Hobbs Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomberg-Maitland Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials Proceedings of the ATS, July 15, 2008; 5(5): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rich The current treatment of pulmonary arterial hypertension: time to redefine success. Chest, October 1, 2006; 130(4): 1198 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension Circulation, June 14, 2005; 111(23): 3105 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, M. Rainisio, and G.e. Simonneau Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival J. Am. Coll. Cardiol., August 21, 2002; 40(4): 780 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats J. Am. Coll. Cardiol., July 3, 2002; 40(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst, S. Rich, A. Widlitz, E. M. Horn, V. McLaughlin, and J. McFarlin Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension* : Open-Label Pilot Study Chest, June 1, 2002; 121(6): 1860 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Blumberg, G. A. J. Riegger, and M. Pfeifer Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise* Chest, May 1, 2002; 121(5): 1566 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]
|
|
|
|
|
|
D. Wax, R. Garofano, and R. J. Barst Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary Hypertension Chest, October 1, 1999; 116(4): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Hill and R. G. Pearl Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension J Appl Physiol, April 1, 1999; 86(4): 1160 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sanchez, M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary hypertension secondary to connective tissue diseases Thorax, March 1, 1999; 54(3): 273 - 277. [Full Text]
|
|
|
|
 |
|
 D. D. Ivy, J. P. Kinsella, J. W. Ziegler, and S. H. Abman Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 875 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hashida, M. Hamada, Y. Shigematsu, S. Ikeda, T. Kuwahara, H. Kawakami, Y. Hara, K. Kodama, K. Kohara, and K. Hiwada Beneficial Hemodynamic Effects of Oral Prostacyclin (PGI2) Analogue, Beraprost Sodium, on a Patient with Primary Pulmonary Hypertension: A Case Report Angiology, February 1, 1998; 49(2): 161 - 164. [Abstract] [PDF]
|
|
|
|
|
|
M. HUMBERT, S. M. TRE, F. CAPRON, B. RAIN, D. MUSSET, and G. SIMONNEAU Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1681 - 1685. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. J. Rubin Primary Pulmonary Hypertension N. Engl. J. Med., January 9, 1997; 336(2): 111 - 117. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst, L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension N. Engl. J. Med., February 1, 1996; 334(5): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Palevsky and A. P. Fishman The Management of Primary Pulmonary Hypertension JAMA, February 27, 1991; 265(8): 1014 - 1020. [Abstract] [PDF]
|
|
|
|
 |
|
 L. J. Rubin, J. Mendoza, M. Hood, M. McGoon, R. Barst, W. B. Williams, J. H. Diehl, J. Crow, and W. Long Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol) Results of a Randomized Trial Ann Intern Med, April 1, 1990; 112(7): 485 - 491. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Jones, T. Higenbottam, D. Wheeldon, J. Kneeshaw, and D. Bethune Prostacyclin, cardiopulmonary bypass and the alveolar capillary membrane Perfusion, July 1, 1986; 1(3): 165 - 173. [Abstract] [PDF]
|
|
|
|
|
|
M. PACKER Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards Ann Intern Med, August 1, 1985; 103(2): 258 - 270. [Abstract] [PDF]
|
|
|
|
|
|
L. J. RUBIN, P. NICOD, L. D. HILLIS, and B. G. FIRTH Treatment of Primary Pulmonary Hypertension with Nifedipine: A Hemodynamic and Scintigraphic Evaluation Ann Intern Med, October 1, 1983; 99(4): 433 - 438. [Abstract] [PDF]
|
|
|
|
|
|
R. G. PEARL, M. H. ROSENTHAL, J. S. SCHROEDER, and J. P. A. ASHTON Acute Hemodynamic Effects of Nitroglycerin in Pulmonary Hypertension Ann Intern Med, July 1, 1983; 99(1): 9 - 13. [Abstract] [PDF]
|
|